Találati lista | Tudóstér

001-es BibID:	BIBFORM029417
Első szerző:	Magyari Ferenc (belgyógyász, hematológus)
Cím:	Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation / Ferenc Magyari, Zsófia Simon, Sándor Barna, Miklós Udvardy, László Váróczy, Árpád Illés
Dátum:	2012
ISSN:	0278-0232 1099-1069
Megjegyzések:	ObjectivesTreatment options for relapsing Hodgkin lymphoma (HL) are controversial after autologous hemopoietic stem cell transplantation (HSCT). Nevertheless, allogeneic HSCT may be curative if it is performed in complete remission.Case reportIn 2007, a 22-year-old female patient was diagnosed with nodular sclerosis subtype of classical HL. Her clinical stage was IIAX with unfavorable prognosis. Eight courses of doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy and involved field irradiation were applied, but after 3 months of complete remission, disseminated relapse was recognised by 18FDG-PET/CT. After two cycles of salvage dexamethasone, cisplatinum, and cytosine arabinoside therapy, further progression was noticed, so the treatment was modified to ifosfamide, gemcitabine, vinorelbine, and prednisone (IGEV) regimen. After two cycles of IGEV regimen, she achieved a complete metabolic remission, which was confirmed by a 18FDG-PET/CT scan again. She was referred for autologous-HSCT, and a successful stem cell collection was performed in August 2008. However, a rapid progression was detected again, so total body irradiation was applied before the conditioning therapy with R-mini-BEAM regimen. The 18FDG-PET/CT scan performed 100?days after the autologous-HSCT was still positive. In December 2009, multiple nodal and extranodal progression was detected, so ifosfamide, carboplatine, etoposide, mesna protection rescue treatment was started, but it was ineffective. Based on sporadic data of the literature, rituximab?bendamustine therapy was started in March 2010. After four cycles, she achieved complete metabolic remission, which was verified by 18FDG-PET/CT. The patient has been referred for an allogeneic HSCT with reduced intensity conditioning.ConclusionsBased on our experience, bendamustine?rituximab salvage therapy can be a suitable option for the treatment of post-transplant progression or relapse of HL.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban bendamustine rituximab Hodgkin lymphoma post-transplantation salvage therapy 18FDG-PET/CT egyetemen (Magyarországon) készült közlemény
Megjelenés:	Hematological Oncology 30 : 2 (2012), p. 98-100. -
További szerzők:	Simon Zsófia (1977-) (belgyógyász, haematológus) Barna Sándor (1982-) (kutató orvos) Udvardy Miklós (1947-) (belgyógyász, haematológus) Váróczy László (1974-) (belgyógyász, haematológus) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: